Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

BACKGROUND: Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimens in the Lake Victoria Basin of Tanza...

Descripción completa

Detalles Bibliográficos
Autores principales: Anywaine, Zacchaeus, Whitworth, Hilary, Kaleebu, Pontiano, Praygod, George, Shukarev, Georgi, Manno, Daniela, Kapiga, Saidi, Grosskurth, Heiner, Kalluvya, Samuel, Bockstal, Viki, Anumendem, Dickson, Luhn, Kerstin, Robinson, Cynthia, Douoguih, Macaya, Watson-Jones, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548900/
https://www.ncbi.nlm.nih.gov/pubmed/30796818
http://dx.doi.org/10.1093/infdis/jiz070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548900/
https://www.ncbi.nlm.nih.gov/pubmed/30796818
http://dx.doi.org/10.1093/infdis/jiz070

Ejemplares similares